Conduit Pharmaceuticals Transitions to Phase 2 of Sarborg Collaboration to Support AI-Driven Drug Development

Conduit Pharmaceuticals Inc. recently announced the successful completion of all milestones in Phase 1 of its strategic collaboration with Sarborg Limited. This transition to Phase 2 marks a positive step forward in Conduit’s strategy to explore the integration advanced artificial intelligence (AI) and cybernetics into its drug development processes. With Phase 1 now complete, the company is pleased to transition to Phase 2, which will focus on the creation of personalized software dashboards to enhance operational efficiency and reporting.

The focus of Phase 1 was to establish a strong foundation for the collaboration with Sarborg, identify key inputs for the algorithmic approach, and align Sarborg’s services with Conduit’s strategic goals. The collaboration, initiated in December 2024, aims to revolutionize drug development by leveraging cutting-edge AI technologies to streamline drug repurposing, accelerate discovery, optimize solid-form identification, and enhance clinical trial monitoring. Phase 1 included teach-in sessions with management, the validation of Conduit’s proprietary inputs that are critical for Sarborg’s cybernetic models and, thirdly, a comprehensive market analysis of cocrystal candidates.

Conduit and Sarborg worked closely to align AI-driven processes with Conduit’s portfolio needs, ensuring that proprietary inputs were tailored to maximize the potential of key assets, including AZD1656, AZD5904, AZD5658, CDT1656, and the AZD1656 cocrystals. Additionally, an in-depth market analysis of cocrystal candidates provided actionable insights into the competitive landscape, patent positioning, and market opportunities.

Conduit is now transitioning to Phase 2, which is expected to focus on building the technological infrastructure necessary to support AI-driven drug development of its current and future portfolio of products. A key deliverable of this phase will be the creation of personalized software dashboards, designed to provide Conduit’s key personnel with real-time access to critical data related to clinical trials, drug discovery, and portfolio management. These dashboards are designed to enable more agile and informed decision-making, allowing the Company to remain focused on delivering impactful clinical trials in autoimmune disorders.

Conduit is a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development. Conduit both acquires and funds the development of Phase 2-ready assets, building an integrated and advanced platform-driven approach powered by artificial intelligence (AI) and cybernetics, and seeking an exit through third-party license deals following successful clinical trials. Led by a highly experienced team of pharmaceutical executives including Dr. David Tapolczay and Dr. Freda Lewis-Hall, this novel approach is a departure from the traditional pharma/biotech business model of taking assets through regulatory approval.